Antimicrobial resistance (AMR) is becoming one of the biggest healthcare challenges worldwide. As concerns grow about antibiotic resistance and its impact on public health, pharmaceutical manufacturers are under increasing pressure to adopt responsible production practices.
In an important development, Gaelic Laboratories has successfully obtained the BSI Kitemark Certification for Minimized Risk of Antimicrobial Resistance (AMR). This achievement highlights the company's commitment to responsible antibiotic manufacturing and environmental sustainability.
A Major Milestone for Gaelic Laboratories
Gaelic Laboratories, a GMP-approved manufacturer of Beta-Lactam antibiotics, has earned the prestigious BSI Kitemark Certification after months of preparation and compliance efforts.
The certification recognizes the company's dedication to minimizing the environmental risks associated with antibiotic production, particularly the development of antimicrobial resistance and aquatic ecotoxicity.
For Gaelic Laboratories, this achievement is more than just a certification. It represents a long-term commitment to ensuring that antibiotic manufacturing is carried out in a way that protects both patients and the environment.
What Is the BSI Kitemark Certification for AMR?
The BSI Kitemark Certification is considered one of the most respected certifications for responsible antibiotic manufacturing.
The certification recently transitioned to align with the Antibiotic Manufacturing Standard released by the AMR Industry Alliance in May 2025. This updated standard became effective on January 1, 2026, and provides clear guidelines for manufacturers throughout the global antibiotic supply chain.
The goal is simple: ensure antibiotics are manufactured responsibly while minimizing the risk of antimicrobial resistance entering the environment.
By obtaining this certification, Gaelic Laboratories demonstrates that its manufacturing processes meet these rigorous international standards.
Why Responsible Antibiotic Manufacturing Matters
When antibiotics are manufactured, improper handling of waste can release active pharmaceutical ingredients into the environment. Over time, these releases may contribute to the development of antimicrobial resistance.
AMR occurs when bacteria evolve and become resistant to antibiotics that once effectively treated infections. This makes infections harder to treat and increases healthcare risks worldwide.
Responsible manufacturing practices help reduce these risks by controlling antibiotic discharge and implementing environmental protection measures throughout the production process.
As governments, healthcare organizations, and pharmaceutical companies continue to address AMR, responsible manufacturing has become a critical part of the solution.
How Gaelic Laboratories Addresses AMR Risks
As part of its certification requirements, Gaelic Laboratories follows a structured framework for managing antibiotic discharge and environmental impact.
The company has committed to:
These measures help ensure that the company's manufacturing operations align with international best practices for sustainable antibiotic production.
A Two-Year Journey Toward Certification
According to Brian Morrissey, General Manager of Gaelic Laboratories, achieving the certification has been a significant accomplishment for the company.
Gaelic Laboratories was established in 2022, making it a relatively young organization in the pharmaceutical manufacturing sector. Work toward obtaining the BSI Kitemark began in 2024, making this achievement the result of nearly two years of focused effort.
The certification reflects the company's determination to establish strong quality and sustainability standards from an early stage of its growth.
Next Goal: Certification for Athlone Laboratories
The company is not stopping here.
Gaelic Laboratories has already started working toward obtaining the same certification for its sister company, Athlone Laboratories.
Once both organizations achieve BSI Kitemark Certification for Minimized Risk of AMR, it will provide customers and partners with additional confidence that their products are manufactured according to internationally recognized environmental and quality standards.
The move also demonstrates a broader commitment across both organizations to responsible pharmaceutical manufacturing.
Recognition from BSI
The achievement has also been acknowledged by BSI, the organization responsible for issuing the certification.
Courtney Soulsby, Global Director of Healthcare Sustainability at BSI, noted that the certification reflects Gaelic Laboratories' commitment to responsible antibiotic production and environmental risk management.
The recognition highlights the company's efforts to support sustainable pharmaceutical manufacturing while contributing to industry-wide initiatives aimed at addressing antimicrobial resistance.
Pathway to AMR Industry Alliance Membership
With the certification now secured, Gaelic Laboratories has become eligible to apply for membership in the AMR Industry Alliance.
The alliance is one of the largest global private-sector coalitions focused on combating antimicrobial resistance. It includes more than 90 pharmaceutical companies, biotechnology firms, diagnostic companies, and industry associations.
The organization works to promote sustainable solutions that help preserve the effectiveness of antibiotics while supporting responsible manufacturing practices worldwide.
Joining the alliance would allow Gaelic Laboratories to collaborate with other industry leaders working toward the same goals.
Supporting Global Access to Essential Medicines
Gaelic Laboratories believes responsible manufacturing and patient access should go hand in hand.
The company continues to focus on producing critical antibiotic medicines while implementing best practices that reduce environmental risks.
Participation in initiatives such as the AMR Industry Alliance would further strengthen the company's ability to contribute to global efforts aimed at preserving antibiotic effectiveness for future generations.
About Gaelic Laboratories
Founded in Ireland in 2022, Gaelic Laboratories is a world-class manufacturer of Beta-Lactam (penicillin) products.
The company manufactures tablets, capsules, and powder-for-suspension formulations under its own brand while also providing contract manufacturing and packaging services.
Its products serve customers across the European Union, United Kingdom, Middle East, and North Africa.
With upgraded manufacturing facilities and a strong focus on quality, Gaelic Laboratories continues to expand its role within the global pharmaceutical supply chain.
About Athlone Laboratories
Athlone Laboratories has been a trusted manufacturer of oral dose Beta-Lactam products since 1974.
The company supplies products to healthcare markets across Europe, Asia-Pacific, Canada, Brazil, Iraq, and several other regions.
Over the years, Athlone Laboratories has built strong partnerships with both local and international pharmaceutical companies, establishing itself as a reliable supplier of antibiotic products.
Conclusion
The BSI Kitemark Certification for Minimized Risk of AMR marks an important achievement for Gaelic Laboratories. It demonstrates the company's commitment to responsible antibiotic manufacturing, environmental protection, and global efforts to combat antimicrobial resistance.
As healthcare systems worldwide continue to address the growing challenge of AMR, manufacturers that adopt sustainable production practices will play an increasingly important role. Gaelic Laboratories' latest certification is a strong step in that direction, reinforcing its commitment to delivering high-quality antibiotics while helping protect the effectiveness of these medicines for future generations.